These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16770788)

  • 1. Thapsigargin resistance in human prostate cancer cells.
    O'Neill JP; Velalar CN; Lee DI; Zhang B; Nakanishi T; Tang Y; Selaru F; Ross D; Meltzer SJ; Hussain A
    Cancer; 2006 Aug; 107(3):649-59. PubMed ID: 16770788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of various amino acid 256 mutations on sarcoplasmic/endoplasmic reticulum Ca2+ ATPase function and their role in the cellular adaptive response to thapsigargin.
    Yu M; Lin J; Khadeer M; Yeh Y; Inesi G; Hussain A
    Arch Biochem Biophys; 1999 Feb; 362(2):225-32. PubMed ID: 9989931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
    Lee DI; Sumbilla C; Lee M; Natesavelalar C; Klein MG; Ross DD; Inesi G; Hussain A
    Arch Biochem Biophys; 2007 Aug; 464(1):19-27. PubMed ID: 17475205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
    Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
    Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of P-glycoprotein in L1210/VCR cells is associated with changes in several endoplasmic reticulum proteins that may be partially responsible for the lack of thapsigargin sensitivity.
    Seres M; Poláková E; Krizanová O; Hudecová S; Klymenko SV; Breier A; Sulová Z
    Gen Physiol Biophys; 2008 Sep; 27(3):211-21. PubMed ID: 18981537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
    Gan L; Yin ZF; Li M
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene amplification and transcriptional upregulation of the sarco/endoplasmic reticulum Ca2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells.
    Rishi AK; Yu M; Tsai-Wu JJ; Belani CP; Fontana JA; Baker DL; Periasamy M; Hussain A
    Nucleic Acids Res; 1998 Oct; 26(19):4529-37. PubMed ID: 9742259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
    Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
    Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment.
    Sigala S; Bodei S; Missale C; Zani D; Simeone C; Cunico SC; Spano PF
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):11-20. PubMed ID: 18280641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of LMO2 expression in the progression of prostate cancer.
    Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
    J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor.
    Sidorkiewicz M; Rebas E; Szymajda M; Ławnicka H; Pawlikowski M; Lachowicz A
    Med Sci Monit; 2009 Apr; 15(4):BR106-10. PubMed ID: 19333191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
    Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Yen WC; Lamph WW
    Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
    Horiguchi A; Zheng R; Shen R; Nanus DM
    Prostate; 2008 Jun; 68(9):975-84. PubMed ID: 18361411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR2 expression correlates with prostate cancer progression.
    Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
    J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.